261 related articles for article (PubMed ID: 27380620)
1. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
2. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
Ye JF; Qi WX; Liu MY; Li Y
Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
[TBL] [Abstract][Full Text] [Related]
3. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
[TBL] [Abstract][Full Text] [Related]
4. Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy.
Du YN; Wei Q; Zhao LJ; Fan CQ; Guo LR; Ye JF; Li Y
Biomed Pharmacother; 2022 Jul; 151():113110. PubMed ID: 35605298
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.
Yang Z; Zhang Q; Xu K; Shan J; Shen J; Liu L; Xu Y; Xia F; Bie P; Zhang X; Cui Y; Bian XW; Qian C
PLoS One; 2012; 7(9):e44802. PubMed ID: 23028626
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas.
Zhao DX; Li ZJ; Zhang Y; Zhang XN; Zhao KC; Li YG; Zhang MM; Yu XW; Liu MY; Li Y
Cell Immunol; 2014; 289(1-2):155-61. PubMed ID: 24838092
[TBL] [Abstract][Full Text] [Related]
7. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
[TBL] [Abstract][Full Text] [Related]
8. Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L.
Liu GY; Li ZJ; Li QL; Jin Y; Zhu YH; Wang YH; Liu MY; Li YG; Li Y
Int Immunopharmacol; 2015 Sep; 28(1):487-93. PubMed ID: 26208317
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.
Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R
Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006
[TBL] [Abstract][Full Text] [Related]
10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
11. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
12. Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells.
Liu FR; Bai S; Feng Q; Pan XY; Song SL; Fang H; Cui J; Yang JL
BMC Cancer; 2018 Nov; 18(1):1087. PubMed ID: 30419845
[TBL] [Abstract][Full Text] [Related]
13. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
14. Dendritic Cell Immunotherapy Combined with Cytokine-Induced Killer Cells Effectively Suppresses Established Hepatocellular Carcinomas in Mice.
Jung NC; Lee JH; Choi HJ; Hwang SU; Song JY; Seo HG; Choi J; Jung SY; Han SG; Lim DS
Immunol Invest; 2016 Aug; 45(6):553-65. PubMed ID: 27410037
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3.
Zhao Y; Li H; Wu R; Li S; Wang P; Wang H; Wang J; Zhou J
PLoS One; 2015; 10(5):e0126726. PubMed ID: 25978371
[TBL] [Abstract][Full Text] [Related]
16. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
17. Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.
Chen P; Luo S; Wen YJ; Li YH; Li J; Wang YS; Du LC; Zhang P; Tang J; Yang DB; Hu HZ; Zhao X; Wei YQ
Cancer Sci; 2014 Nov; 105(11):1393-401. PubMed ID: 25230206
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-15-transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model.
Peng Z; Liang W; Li Z; Xu Y; Chen L
Cell Biol Int; 2016 Feb; 40(2):204-13. PubMed ID: 26503216
[TBL] [Abstract][Full Text] [Related]
19.
Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
Front Immunol; 2021; 12():610042. PubMed ID: 33679747
[TBL] [Abstract][Full Text] [Related]
20. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]